Stock 2105 LAEKNA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Laekna, Inc.

Equities

2105

KYG5340S1093

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:27 2024-07-12 am EDT 		5-day change 1st Jan Change
5.39 HKD +1.89% Intraday chart for Laekna, Inc. +11.59% -72.91%
Jun. 26 Laekna Administers First Dose of Weight Loss Drug in China During Phase I Clinical Trials; Shares Gain 6% MT
Jun. 26 Laekna, Inc Doses Subject in Phase I Clinical Trial of LAE102 for the Treatment of Obesity CI
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In

Latest news about Laekna, Inc.

Laekna Administers First Dose of Weight Loss Drug in China During Phase I Clinical Trials; Shares Gain 6% MT
Laekna, Inc Doses Subject in Phase I Clinical Trial of LAE102 for the Treatment of Obesity CI
Laekna Enlists First Patient for Phase 3 Trial for Breast Cancer Treatment in China; Shares Rise 4% MT
Laekna, Inc. Announces First Patient Enrolled in Phase III Clinical Trial of LAE002 (AFURESERTIB) Plus Fulvestrant in Patients with HR+/HER2- Local Advanced or Metastatic Breast Cancer CI
US FDA Gives Green Light to Laekna's Phase 3 Trial for Prostate Cancer Drug; Shares Rise 8% MT
Laekna, Inc. Announces Approval by the U.S. Food and Drug Administrationfor the Phase III Clinical Trial Protocol Of LAE002 (Afuresertib) Plus LAE001 for the Treatment Ofprostate Cancer CI
Laekna Gets Investigational New Drug Approval from Chinese Regulator for Obesity Drug MT
Lekna, Inc. Obtains IND Approval from the CDE for LAE102 CI
Laekna Scores FDA Nod for Obesity Drug LAE102 MT
Lekna, Inc. Obtains Investigational New Drug Approval from the U.S. Food and Drug Administration for LAE102 CI
Laekna Shrinks Loss in Fiscal 2023 MT
Laekna, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Laekna Submits New Drug Application to US FDA for Anti-Obesity Drug MT
Lekna, Inc. Submits Investigational New Drug Application for LAE102 for the Treatment of Obtains Treatment of Obtains Treatment to the U.S. Food and Drug Administration CI
Laekna's LAE102 IND Application Accepted by Chinese Drug Authorities MT
Laekna, Inc. Announces the Centre for Drug Evaluation of the National Medical Products Administration of China Accepts the Investigational New Drug Application for Lae102 CI
Laekna, Inc. Announces Management Changes CI
Laekna's Phase 2 Trial for Ovarian Cancer Treatment Shows Reduced Risk of Disease Progression; Shares Plunge 34% MT
Laekna, Inc. Announces Top-Line Data of the Global MRCT Phase II Registrational Trial (PROFECTA-II) in Both the U.S. and China CI
Laekna, Inc. Announces Appointment of Chau Kwok Keung as Chief Financial Officer CI
Laekna, Inc. Announces Executive Changes CI
326,372,350 Shares of Laekna, Inc. are subject to a Lock-Up Agreement Ending on 29-DEC-2023. CI
Laekna, Inc.(SEHK:2105) added to S&P Global BMI Index CI
Laekna Presents Data from Phase 1B Trial for Cancer Treatment MT
Laekna, Inc. Announces Presentation of the Study Results from Core Product Furesertib at the 2023 SABCS CI

Chart Laekna, Inc.

Chart Laekna, Inc.
More charts

Company Profile

Laekna Inc is an investment holding company mainly engaged in the discovery, development and commercialization of innovative therapies for cancer, liver diseases and obesity. The Company is still in the research and development stage. The Company's pipeline products include Afuresertib (LAE002), LAE001, LAE109, LAE111, LAE112, LAE113, LAE117, LAE118, LAE119, LAE102, LAE103, LAE104, LAE105, LAE106, LAE120, LAE123, and others. The Afuresertib is an adenosine triphosphate (ATP) competitive AKT inhibitor. The LAE001 is an androgen synthesis inhibitor that can inhibit CYP17A1 and CYP11B2 at the same time. The Company mainly conducts business in the Chinese, America, European, Korean, and other markets.
Sector
Biotechnology & Medical Research
More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

1st Jan change Capi.
LAEKNA, INC. Stock Laekna, Inc.
-72.91% 269M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+20.12% 126B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+25.25% 119B
ARGENX SE Stock argenx SE
+25.56% 27.95B
BIONTECH SE Stock BioNTech SE
-19.51% 20.5B
GENMAB A/S Stock Genmab A/S
-14.36% 17.12B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.63% 16.1B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-46.67% 14.97B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+11.89% 14.84B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+57.74% 14.38B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 2105 Stock
  4. News Laekna, Inc.
  5. Laekna Scores FDA Nod for Obesity Drug LAE102